PYXS

Pyxis Oncology, Inc. [PYXS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PYXS Stock Summary

Top 10 Correlated ETFs

PYXS


Top 10 Correlated Stocks

PYXS


In the News

01:07 29 Mar 2024 PYXS

3 Biotech Stocks to Buy on the Dip: March 2024

One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.

01:01 29 Mar 2024 PYXS

All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy

Pyxis Oncology (PYXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

02:58 29 Mar 2024 PYXS

From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires

Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.

04:30 29 Mar 2024 PYXS

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, where members of management will also host investor one-on-one meetings.

04:45 29 Mar 2024 PYXS

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models

06:00 29 Mar 2024 PYXS

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024

With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.

11:17 29 Mar 2024 PYXS

Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology, Inc. (PYXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

04:01 29 Mar 2024 PYXS

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will present a company overview at the BTIG Virtual Biotechnology Conference on August 7, 2023 at 3:00 PM EST. The Pyxis Oncology management team will also host investor meetings that same day. To join the conference, email info@btig.com.

01:32 29 Mar 2024 PYXS

Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

02:59 29 Mar 2024 PYXS

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead product candidates, PYX-201 and PYX-106, are currently in Phase 1 clinical trials, with promising preclinical results and unique targeting mechanisms. Pyxis Oncology presents a 'Buy' opportunity for high-risk-tolerant investors, but investors should monitor the progress of ongoing Phase 1 trials and the competitive landscape.

PYXS Financial details

Company Rating
Neutral
Market Cap
178.57M
Income
-72.08M
Revenue
0
Book val./share
2.16
Cash/share
2.08
Dividend
-
Dividend %
-
Employees
67
Optionable
No
Shortable
Yes
Earnings
11 May 2024
P/E
-2.63
Forward P/E
-2.94
PEG
0.51
P/S
-
P/B
0.64
P/C
2.05
P/FCF
-1.16
Quick Ratio
4.69
Current Ratio
4.91
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
-1.74
EPS next Y
-1.45
EPS next Q
-0.37
EPS this Y
-48.18%
EPS next Y
-16.52%
EPS next 5Y
-35.06%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-51.79%
-
-
-
-
SMA20
-33.33%
SMA50
100%
SMA100
100%
Inst Own
9.96%
Inst Trans
0.37%
ROA
-18%
ROE
-23%
ROC
-0.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
58.13M
Shs Float
39.91M
-
-
-
-
Target Price
-
52W Range
1.35-6.92
52W High
-29%
52W Low
+326%
RSI
45
Rel Volume
0.49
Avg Volume
791.22K
Volume
386.91K
Perf Week
-14.11%
Perf Month
-21.83%
Perf Quarter
108.82%
Perf Half Y
129.03%
-
-
-
-
Beta
1.634
-
-
Volatility
0.23%, 0.88%
Prev Close
0%
Price
4.26
Change
3.15%

PYXS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.12-0.58-9.6-3.57-1.85
Operating cash flow per share
-0.1-0.46-4.16-2.7-1.77
Free cash flow per share
-0.1-0.52-4.22-2.9-1.94
Cash per share
0.90.3732.355.433.03
Book value per share
-0.13-0.7130.774.873.15
Tangible book value per share
-0.13-0.7130.774.872.6
Share holders equity per share
-0.13-0.7130.774.873.15
Interest debt per share
00.040.020.490.53
Market cap
290.07M292.07M93.17M44.26M71.83M
Enterprise value
270.4M284.77M-181.4M-116.11M82.02M
P/E ratio
-108.85-22.89-1.14-0.38-0.97
Price to sales ratio
00000
POCF ratio
-129.56-28.96-2.64-0.5-1.02
PFCF ratio
-129.56-25.25-2.6-0.46-0.93
P/B Ratio
-100.93-18.670.360.280.57
PTB ratio
-100.93-18.670.360.280.57
EV to sales
00000
Enterprise value over EBITDA
-93.92-22.922.860.94-1
EV to operating cash flow
-120.77-28.245.131.3-1.16
EV to free cash flow
-120.77-24.625.061.21-1.06
Earnings yield
-0.01-0.04-0.88-2.66-1.03
Free cash flow yield
-0.01-0.04-0.38-2.16-1.08
Debt to equity
-0.01-0.0500.120.17
Debt to assets
00.0800.090.12
Net debt to EBITDA
6.830.594.321.3-0.12
Current ratio
26.882.214.95.94.84
Interest coverage
00044.670
Income quality
0.810.790.460.740.96
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000.14
Capex to operating cash flow
00.150.020.070.1
Capex to revenue
00000
Capex to depreciation
0-3.16-0.83-9.03-3.49
Stock based compensation to revenue
00000
Graham number
0.63.0381.5219.7811.45
ROIC
0.970.91-0.29-0.61-0.49
Return on tangible assets
-0.13-1.26-0.29-0.56-0.49
Graham Net
-0.14-0.830.143.921.88
Working capital
18.97M4.41M259.97M154.98M98.85M
Tangible asset value
-2.87M-15.65M261.31M160.82M103.56M
Net current asset value
-2.98M-17.69M259.97M136.06M78.75M
Invested capital
-0.01-0.0500.120.17
Average receivables
000299K299K
Average payables
0784K6.51M9.52M5.5M
Average inventory
000437K437K
Days sales outstanding
00000
Days payables outstanding
0885.373.49K1.41K0
Days of inventory on hand
000173.750
Receivables turnover
00000
Payables turnover
00.410.10.260
Inventory turnover
0002.10
ROE
0.930.82-0.31-0.73-0.59
Capex per share
0-0.07-0.06-0.19-0.17

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
0.69-0.5-0.41-0.56-0.27
Operating cash flow per share
-0.53-0.76-0.29-0.430
Free cash flow per share
-0.58-0.88-0.35-0.430
Cash per share
5.434.223.723.222.08
Book value per share
4.874.33.783.342.16
Tangible book value per share
4.874.33.782.82.2
Share holders equity per share
4.874.33.783.342.16
Interest debt per share
-1.210.520.550.520.02
Market cap
44.26M141.76M98.28M82.25M104.64M
Enterprise value
-116.11M108.95M93.64M89.15M114.84M
P/E ratio
0.48-2.02-1.55-0.89-1.68
Price to sales ratio
00000
POCF ratio
-2.55-5.28-8.91-4.680
PFCF ratio
-2.3-4.54-7.39-4.660
P/B Ratio
0.280.930.680.60.83
PTB ratio
0.280.930.680.60.83
EV to sales
00000
Enterprise value over EBITDA
3.07-5.25-5.32-3.52-6.46
EV to operating cash flow
6.68-4.06-8.49-5.070
EV to free cash flow
6.03-3.49-7.05-5.050
Earnings yield
0.52-0.12-0.16-0.28-0.15
Free cash flow yield
-0.43-0.22-0.14-0.210
Debt to equity
0.120.130.150.160.01
Debt to assets
0.090.110.120.120.01
Net debt to EBITDA
4.241.580.26-0.27-0.57
Current ratio
5.913.4616.184.914.84
Interest coverage
0.6412.25000
Income quality
0.481.390.690.760
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0000.120
Capex to operating cash flow
0.110.160.200
Capex to revenue
00000
Capex to depreciation
-9.68-23.19-4.31-0.120
Stock based compensation to revenue
00000
Graham number
8.716.935.946.473.61
ROIC
0.12-0.1-0.09-0.14-0.12
Return on tangible assets
0.11-0.1-0.09-0.14-0.09
Graham Net
4.013.362.942.041.29
Working capital
154.98M144.58M140.08M110.76M98.85M
Tangible asset value
160.82M152.16M145.28M115.65M127.87M
Net current asset value
136.06M125.54M119.35M90.35M78.75M
Invested capital
0.120.130.150.160.01
Average receivables
299K299K000
Average payables
6.3M5.56M2.67M2.31M3.6M
Average inventory
3.17M3.17M000
Days sales outstanding
00000
Days payables outstanding
1.38K1.08K168.03440.030
Days of inventory on hand
1.23K0000
Receivables turnover
00000
Payables turnover
0.070.080.540.20
Inventory turnover
0.070000
ROE
0.14-0.12-0.11-0.17-0.12
Capex per share
-0.06-0.12-0.0600

PYXS Frequently Asked Questions

What is Pyxis Oncology, Inc. stock symbol ?

Pyxis Oncology, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol PYXS

What is Pyxis Oncology, Inc. stock quote today ?

Pyxis Oncology, Inc. stock price is $4.26 today.

Is Pyxis Oncology, Inc. stock public?

Yes, Pyxis Oncology, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap